Endocare Posts $739,454 Loss
- Share via
IRVINE — Endocare Inc., which makes medical devices to treat prostate disease, incurred a net loss of $739,454, or 10 cents a share, for the first quarter, which included a noncash charge of $50,000 in interest on a note that was converted to equity. For the first quarter last year, the company lost $577,584, or 10 cents a share. Revenue increased 83% to $679,668 from $370,656.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
